Stryker CEO Kevin Lobo says robots now do 2 of every 3 knee replacements—and he won’t build them in China because ‘the IP is a massive worry’
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Stryker CEO Kevin Lobo said robots now assist in two of every three knee replacements the company performs, as the medtech firm commits $400 million to develop a soft-tissue surgical robot. Lobo told Fortune that Chinese competitors are "knocking off" many rival robots, and he ruled out building the new system in China because "the IP is a massive worry." The disclosure underscores how quickly robotics has become the standard of care in orthopedics and how fiercely cost pressure from Chinese imitators is shaping where Western medtech firms manufacture. Stryker's $400 million bet extends its robot portfolio beyond orthopedics into soft-tissue surgery, a segment where Intuitive Surgical has long dominated. Investors will watch adoption metrics for the new platform and whether Stryker shifts more production outside China as IP and tariff risks mount.
Muhabbit's AI wrote this summary in its own words from Fortune's report. It can get details wrong, so check the source.
Named in this story
Stryker (SYK), Kevin Lobo, China, Fortune
A linked name opens that asset's sentiment page.